Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
In a double-blind, randomised multicentre study buflomedil, a vasoactive substance, was compared with placebo in the treatment of 93 patients with chronic arterial occlusive disease. After a run-in period of four weeks the patients received either buflomedil (600 mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the differences in the improvement between the two groups were highly significant and in favour of buflomedil: for the pain-free walking distance p less than 0.001 and for the total walking distance p less than 0.01. The results indicate that buflomedil has a beneficial effect on the symptoms and lengthens the walking distance in patients with arterial occlusive disease.
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D007866:Leg / Q000098:blood supply; D008875:Middle Aged; D010146:Pain; D011759:Pyrrolidines / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D011759:Pyrrolidines; D014665:Vasodilator Agents; C010651:buflomedil